Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
Ella Day | May 7, 2025 | News story | Mergers and Acquisitions | Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its leading programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
While Alchemab will take the programme through phase 1 clinical trials, Lily will lead further development and commercialisation. The transaction is worth a total of $415m.
Using machine learning and artificial intelligence (AI), Alchemab studies antibodies with unique resilience to untreatable diseases, seeking to develop these into therapies.
American biopharma company, Lilly, works on therapies and clinical trials for leading health problems such as cancer, Alzheimer’s disease, obesity and diabetes.
CEO of Alchemab, Jane Osbourn, commented: “With Lilly’s deep expertise in neurological conditions, they are ideally placed to speedily advance ATLX-1282 through the clinic, and maximise the potential to help patients.”
ALS is a rare and terminal neurodegenerative disease for which there is no known cure. It leads to a progressive loss of motor neurons that control voluntary muscles, and average survival from onset to death is two to four years.
The transaction follows on from a previous agreement with Lilly in January to discover, develop and commercialise up to five novel therapeutic candidates for ALS.
Through the collaboration, Alchemab hopes to advance the scope of its work. Osbourn added: “The transaction will support our work to progress our pipeline and we look forward to unveiling highly differentiated assets in these areas in due course.”
Ella Day
7/5/25
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
